Brivanib (BMS-540215)

Catalog No. A10254

Brivanib (BMS-540215)是一种VEGFR-2抑制剂，IC50为25 nM，Ki为26 nM。

Product Citations

Hirosumi Tamura, .et al. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues, Oncol Rep, 2018, Aug; 40(2): 635-646 PMID: 29917168

Technical details

Catalog Num	A10254
M. Wt	370.4
Formula	C19H19FN4O3
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	649735-46-6
Synonyms	BMS540215
SMILES	CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)O)C

Biological Activity

Brivanib (BMS-540215)是一种VEGFR-2抑制剂，IC50为25 nM，Ki为26 nM。

Targets

Target	Value
VEGFR2	IC50: 25nM
Flk1	IC50: 89nM
FGFR1	IC50: 148nM
VEGFR1	IC50: 380nM
EGFR	IC50: >1.9μM
LCK	IC50: >2.5μM
PDGFRβ	IC50: >6μM
PKCα	IC50: >25μM
JAK3	IC50: >50μM

Solubility *

In vitro	DMSO	71 mg/mL (191.69 mM)
	Water	Insoluble
	Ethanol	3 mg/mL (8.09 mM)
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	27 mL	134.99 mL	269.98 mL
0.5 mM	5.4 mL	27 mL	54 mL
1 mM	2.7 mL	13.5 mL	27 mL
5 mM	0.54 mL	2.7 mL	5.4 mL

*The above data is based on the productmolecular weight 370.4. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.